Skip Ribbon Commands
Skip to main content

Naloxone Distribution

PI: Jane Buxton (BC Center for Disease Control)

Leadership Group: Katherine Rittenbach (University of Alberta, AB); Carole Morisette (Direction de la santé publique de Montréa, QC); Pamela Leece (Ontario Public Health, ON)​

As Canada finds itself amidst an evolving opioid public health crisis, including escalating mortality from overdose, the provision of ‘naloxone’ has been recognized as a key emergency measure and targeted tool to reverse opioid overdose and prevent mortality. Naloxone availability and distribution has evolved in different jurisdictions across Canada, in rather diversified ways; for example, federal and provincial legislation/regulations have been modified to expand naloxone distribution, and different naloxone distribution models and practices (e.g., injection/nasal; multiple availability sources; provision through first responders, peers, take-home programs) have been proposed or implemented in different jurisdictions, including provinces and/or municipalities. The first phase of the project is: 

Environmental Scan of Naloxone Parameters across Canada

Key parameters of current naloxone legislation/regulations, modes/products, availability, distribution practice across Canadian jurisdictions are not systematically documented. A previous cross-sectional effort was conducted some years ago but was limited to the state of ‘take-home naloxone’ and is now outdated. Objectives include:
  • Use key informant interviews and systmatic review to answer key questions in naloxone safety, distribution and use to inform national best practices
  • Support outcomes research (including data analysis, literature review, writing/copy-editing, dissemination) for projects related to naloxone distribution
  • Disseminate and distribute final scan to key stakeholders and policymakers to inform research and policy/practice